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Enzymatic oxidation of cholesterol generates numerous distinct bile acids that function both as detergents
that facilitate digestion and absorption of dietary lipids, and as hormones that activate four distinct receptors.
Activation of these receptors alters gene expression in multiple tissues, leading to changes not only in bile
acid metabolism but also in glucose homeostasis, lipid and lipoprotein metabolism, energy expenditure,
intestinal motility and bacterial growth, inflammation, liver regeneration, and hepatocarcinogenesis. This
review covers the roles of specific bile acids, synthetic agonists, and their cognate receptors in controlling
these diverse functions, as well as their current use in treating human diseases.An Overview and Brief History of Bile Acids
The first description of a bile acid was made in 1848 when cholic
acid (CA) was discovered in ox gall. Subsequent studies in the
early 1900s identified additional bile acids that included litho-
cholic acid (LCA), chenodeoxycholic acid (CDCA), ursodeoxy-
cholic acid (UDCA), and muricholic acid (MCA) from ox, goose,
bear, and rodents, respectively, as described by Wieland in his
1928Nobel lecture (Wieland, 1966). More sophisticatedmethod-
ologies subsequently led to the identification of multiple addi-
tional species of bile acids, including deoxycholic acid (DCA),
that contribute to the ‘‘bile acid pool’’ (2–4 g in humans) (Figures
1A and 1B). The relative concentrations of individual bile acids
within the bile acid pool of different mammals can vary signifi-
cantly (Figure 1B) and may affect bile acid-dependent signaling.
Bile acids are known to play a number of roles in lipid meta-
bolism. First, bile acids are essential for the formation of mixed
micelles in the small intestine that facilitate solubilization, diges-
tion, and absorption of dietary lipids and fat-soluble vitamins.
Second, the micelles present in the gall bladder serve to solubi-
lize cholesterol in bile, thus impairing cholesterol crystallization
and gallstone formation. Third, bile salts induce bile flow from
hepatocytes into the bile canaliculi and then gall bladder. Fourth,
the hepatic conversion of cholesterol to bile acids and the sub-
sequent excretion of bile acids in the feces represent the major
route for cholesterol excretion that is important in whole-body
sterol homeostasis. Bile is also thought to have a bacteriostatic
function that maintains sterility in the biliary tree. Consistent with
these roles, disruption of normal bile acid synthesis and meta-
bolism is associated with cholestasis, gallstones, inflammation,
malabsorption of lipids and fat-soluble vitamins, bacterial over-
growth in the small intestine, atherosclerosis, neurological dis-
eases, and various inborn errors such as progressive familial
intrahepatic cholestasis types I–III (PFIC I-III).
The discovery that specific bile acids differentially activate
three nuclear receptors, namely farnesoid X receptor (FXR),
pregnane X receptor (PXR), and vitamin D receptor (VDR) and
one G protein-coupled receptor (TGR5), identified bile acids as
hormones that alter multiple metabolic pathways in many tis-
sues. The synthesis and use of specific agonists for FXR or
TGR5 in rodents, together with preliminary clinical findings withFXR agonists, suggest that such agonists may prove useful in
the treatment of a number of diseases.
In this review, we emphasize the mechanisms that maintain
bile acid homeostasis through the regulation of bile acid synthe-
sis and transport, and the diverse roles that these bile acids have
on the four bile acid-responsive receptors. We also briefly
discuss the current clinical uses of bile acids and FXR agonists
to treat human diseases. We cite only a small fraction of the
appropriate references, as the literature on these topics is ex-
traordinarily extensive. We refer those interested to many excel-
lent related reviews on bile acids, FXR, or TGR5 (Angelin et al.,
2012; Chiang, 2009; Keitel and Ha¨ussinger, 2012; Lefebvre
et al., 2009; Matsubara et al., 2013; Pols et al., 2011b; Porez
et al., 2012; Russell, 2003, 2009; Thomas et al., 2008).
An Overview of Bile Acid Structure and Function
Bile acids are soluble products derived from the catabolism of
highly insoluble cholesterol (Figure 1A and Figure 2A). In general,
bile acids are composed of four steroid rings forming a hydrocar-
bon lattice with a convex hydrophobic face and a concave
hydrophilic face containing hydroxyl groups, and a short five
carbon acidic side chain that is subsequently amidated with
taurine or glycine (Figure 1A). This amphipathic structure gives
bile acids the detergent properties that allow for micelle forma-
tion and facilitates the digestion and absorption of dietary lipids
and fat-soluble vitamins A, D, E, and K from the small intestine.
The presence or absence of hydroxyl groups in the a or b orien-
tation at positions 3, 6, 7, and 12 on the steroid backbone
(Figure 1A) affects both their solubility and their hydrophobicity
(rank order from hydrophobic to hydrophilic: LCA > DCA >
CDCA > CA > UDCA > MCA). These small structural differences
also have significant effects in the specificity of activation of
the four bile acid-responsive receptors (Table 1). Surprisingly,
a recent study demonstrated that b-muricholic acid, a major
bile acid in rodents, functions as an antagonist of FXR (Sayin
et al., 2013).
Bile Acid Synthesis and the Enterohepatic Circulation
At least 17 enzymes are involved in the modification of the
cholesterol steroid ring, cleavage of the side chain, andCell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 657
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Figure 1. Synthesis of Bile Acids and the
Bile Acid Pool
(A) The conversion of the 27 carbon cholesterol to
primary and secondary 24 carbon bile acids by
liver enzymes and the microbiome/gut flora is
shown. Representative primary and secondary
bile acids together with the orientation of the
hydroxyls are indicated.
(B) Relative bile acid composition in the human
(modified from Hofmann, 2010) and mouse bile
acid pool (modified from Kerr et al., 2002).
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bile salts (Figure 2A) (Russell, 2003, 2009). The finding that
patients with inborn errors of nine of these genes exhibit various
diseases, including neonatal cholestasis, neurological defects,
and malabsorption of fat and fat-soluble vitamins, emphasizes
the critical requirement for cholesterol catabolism to bile acids
(Heubi et al., 2007).
The classic or neutral bile acid pathway is regulated by choles-
terol 7a-hydroxylase (CYP7A1), a cytochrome P450 enzyme that
converts cholesterol to 7a-hydroxycholesterol (Figure 2A, inset).
The latter intermediate is either converted to CDCA or is con-
verted to CA by a pathway that depends on 12-hydroxylation
of the steroid ring by CYP8B1 (Figure 2A). Deletion of Cyp7a1
in mice suggested that this pathway contributes 75% of total
bile acid synthesis (Schwarz et al., 1996). The alternative, or
acidic, pathway generates CDCA and accounts for 9% and
25% of the total bile acid synthesis in humans and mice, respec-
tively (Duane and Javitt, 1999; Schwarz et al., 2001) (Figure 2A,
inset). Although initially identified in humans (Anderson et al.,
1972), Russell and colleagues characterized the alternative
pathway when they discovered that Cyp7a1–/– mice had high
postnatal lethality, but the few surviving mice actually synthe-
sized bile acids (Ishibashi et al., 1996; Russell, 2009). Subse-
quent studies demonstrated that this latter pathway was depen-
dent upon oxidation of the cholesterol side chain at C27 by
CYP27A1, prior to hydroxylation of the steroid ring by oxysterol658 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.7a-hydroxylase (CYP7B1) (Figure 2A,
inset). C25- and C24-(S)-hydroxycholes-
terols can also enter the alternative
pathway to generate bile acids (Schwarz
et al., 1996). Most of the oxysterols that
feed into the alternative bile acid synthetic
pathway are derived from the liver or
macrophages (Russell, 2003). However,
the brain and lung also contribute oxy-
sterols to the alternative pathway as
they synthesize 24-, 25-, or 27-hydroxy-
cholesterols that are subsequently trans-
ported to the liver for metabolism by the
alternative bile acid pathway (Bjo¨rkhem
et al., 2010).
Prior to secretion, bile acids are conju-
gated with taurine or glycine (Figure 2A), a
process that lowers their pKa and in-
creases their solubility, thereby facili-
tating micelle formation in the acidic
environment of the duodenum. However,unlike nonconjugated bile acids that can diffuse across mem-
branes, bile salts require a transmembrane transporter to move
them across membranes. The secretion of bile salts from hepa-
tocytes into the canaliculi requires the bile salt export protein
(BSEP; ABCB11), while transport of phospholipids requires
ABCB4 (also known as MDR3 in humans or MDR2 in mice) (Fig-
ure 2A). Although cholesterol efflux into bile requires ABCG5/
ABCG8, there is an additional requirement for ABCB4, consis-
tent with phospholipids in the bile canaliculi functioning as a
sink to accept cholesterol that has been flipped across the apical
membrane by ABCG5/ABCG8 (Figure 2A) (Graf et al., 2003;
Nicolaou et al., 2012; Wang et al., 2009a). The importance of
these transporters can be seen in patients or mice that have
inactivating mutations or gene deletions leading to loss of func-
tion. For example, loss of BSEP results in progressive familial
intrahepatic cholestasis, a disease wherein bile salts accumulate
in the liver to toxic levels (Nicolaou et al., 2012).
The bile salts together with phospholipids and cholesterol are
passed into the gall bladder, where they are concentrated to
form bile, which is composed of 85% water. The remaining
solute is a complex mixture of bile salts (67%), phospholipids
(22%), and cholesterol (4%), together with electrolytes, minerals,
and minor levels of proteins, plus bilirubin and biliverdin pig-
ments, which give it a yellow-green or even orange hue (Dawson,
2010). Small amounts of mucus and secretory IgA (sIgA) may
contribute to the bacteriostatic functions of bile (Sung et al.,
A B
Figure 2. Bile Acid Metabolism in Liver and Intestine
(A) A cartoon of hepatocytes showing the classic (neutral) and alternative (acidic) bile acid biosynthetic pathways that generate glycine- or taurine-conjugated bile
acids (BA), including cholic, chenodeoxycholic, and muricholic acids (inset). The location of the lipid transporters BSEP, MDR2/3, and ABCG5/ABCG8 on the
apical membrane, and the location of NTCP and OATP transporters that facilitate recovery of bile acids from the blood are also shown. FGF15, secreted into the
portal blood from the intestine, is shown bound to FGFR4/b-Klotho, leading to suppression of bile acid (BA) synthesis. Three representative FXR target genes
(SHP, BSEP, and MDR2/3) are shown in the nucleus.
(B) A cartoon of enterocytes in the distal ileum showing bile acid absorption from the lumen occurring via ASBT and bile acid efflux out of the cell via OSTa/OSTb.
Representative FXR target genes (SHP, FGF15/19, IBABP, OSTa, and OSTb) are shown as well as the secretion of FGF15 into the portal blood.
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solubilizing cholesterol in bile, thus preventing cholesterol crys-
tallization and the formation of cholesterol gallstones (Wang
et al., 2009a).
The presence of dietary fat in the duodenum causes the secre-
tion of cholecystokinin (CCK) from the intestinal mucosa into the
circulation, which in turn promotes contraction of smooth
muscle cells of the gall bladder and relaxation of the sphincter
of Oddi, thus allowing bile to enter the duodenum (Chandra
and Liddle, 2007). In the lumen the bile salt-containing mixed
micelles facilitate absorption of the fat-soluble vitamins A, D,
and E and the metabolism of dietary lipids by pancreatic
enzymes, prior to their absorption. The gall bladder itself is not
essential, since rats, which lack a gall bladder, and patients
who have undergone cholecystectomy (removal of the gall
bladder) are still able to absorb lipids from the diet as a result
of direct secretion of bile into the duodenum.
Following secretion of bile salts into the duodenum, most
(95%) are reabsorbed in the distal ileum via the apical
sodium-dependent transporter (ASBT) present on the entero-
cyte brush border (Figure 2B). Intestinal bile acid-binding protein
(IBABP/fatty acid-binding protein subclass 6/FABP6) may facili-
tate transport of bile salts across the enterocyte to the basolat-
eral membrane where they are effluxed into the blood by the
heterodimeric transporter OSTa/OSTb (Figure 2B) (Chiang,
2009; Dawson et al., 2010). However, a small percentage of
the bile salts escape resorption and are deconjugated by bacte-
rial flora before either being absorbed or converted into second-
ary bile acids (Figure 1A). Secondary bile acidsmay be absorbed
by passive processes or excreted in the feces. The absorbed
primary and secondary bile acids and salts are transported
back to the liver where most, but not all, are actively transportedinto hepatocytes by sodium (Na+)-taurocholate cotransporting
polypeptide (NTCP/SLC10A1) and organic anion transporters
(OATPs; e.g., OAT1B2) that mediate the uptake of bile salts
and bile acids, respectively (Figure 2A) (Chiang, 2009; Thomas
et al., 2008). In the liver, bile acids are reconjugated and then re-
secreted together with newly synthesized bile salts to complete
one cycle of the enterohepatic circulation. One exception is the
secondary bile acid LCA that is present at low levels and is hep-
atotoxic at elevated concentrations. The small amount of LCA
that is returned to the liver is sulfated prior to secretion into bile
and excreted in the feces (Wang et al., 2009a).
In humans, the bile acid pool contains 2–4 g of bile acids.
Recycling of bile acids/salts between the liver and intestine
occurs six to ten times each day and transports 20–40 g bile
acids. However, 0.2–0.6 g of bile acids are excreted in the
feces each day, an amount that must be replenished by de
novo synthesis from cholesterol (Dawson, 2010). It is notable
that the hepatic recovery of bile acids from the portal vein
(bile acid concentration 10–80 mM) is incomplete (Angelin
et al., 1982), thus accounting for the presence of low levels of
bile acids (2–10 mM) in the peripheral circulation of humans
and mice (Angelin et al., 1982; Zhang et al., 2011b). As might
be expected, the concentrations of individual bile acids in the
portal vein and systemic blood vary with food consumption,
as resorption of bile acids is greatest in the postprandial period
(Angelin et al., 1982). The relatively high concentrations of bile
acids in the tissues involved in the enterohepatic circulation
(liver, bile ducts, gall bladder, and intestine) is sufficient to
activate receptors present in these tissues (Table 1; see below).
However, since the total concentration of bile acids in the
peripheral circulation is low under normal physiological con-
ditions, additional studies are necessary to determine theCell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 659
Table 1. Functions and Sites of Action of Bile Acids
Function Site of Action
Micelles prevent cholesterol
crystallization
Gall bladder and bile duct
Micelles facilitate lipid digestion by
pancreatic enzymes
Intestinal lumen
Micelles facilitate vitamin A, D,
E, and K absorption
Intestinal lumen
Impair bacterial overgrowth Intestinal lumen
Maintain intestinal barrier to
infection
Intestine
FXR activation: CDCA > DCA >
LCA[ CA
Liver, ileum, kidney, adrenal
gland
TGR5 activation: LCA > DCA >
CDCA > CA (taurine conjugation
reduces EC50)
Gall bladder, intestinal
neuroendocrine cells, enteric
neurons, brown adipose tissue,
macrophages, brain
PXR activation: LCA3-keto-LCA Intestine, liver
VDR activation: LCA3-keto-LCA Ileal enterocytes
Summary of known functions and sites of action of bile acids present in
the rodent and human bile acid pool.
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peripheral tissues.
Bile Acids Affect the Microbiome and Vice Versa
Intestinal microbial organisms play an important role in bile acid
metabolism, as they readily deconjugate and 7a-dehydroxylate
primary bile salts that escape reabsorption in the distal ileum
and convert them to secondary bile acids (LCA, DCA, UDCA,
and, in rodents, u-MCA) (Figure 1A) (Ridlon et al., 2006). How-
ever, these secondary bile acids synthesized by the microbiome
comprise only a small percent of the normal bile acid pool
(Figure 1B).
Recent studies have shown that the microbiome affects not
only the composition of the bile acid pool but also the expression
of genes controlled by the bile acid-activated receptor FXR
(Swann et al., 2011). As compared to rats with normal flora,
germ-free rats were shown to have reduced levels of bile acids
in various tissues, an almost total loss of unconjugated and
glycine- conjugated bile acids, a significant increase in taurine-
conjugated bile salts, and changes in the hepatic expression of
genes regulated by the bile acid-responsive nuclear receptor
FXR (Swann et al., 2011). More modest changes were observed
following treatment of rats with antibiotics that partially reduce
the microbiome (Swann et al., 2011). In contrast, bile acid levels
were significantly increased in the livers of germ-free C57BL/6
mice (Selwyn and Klaassen, 2012). Although the reasons for
these differences between germ-free rats and mice remain to
be elucidated, both studies suggest that the microbiome is an
important modulator of bile acid metabolism and function.
Dietary components can also affect the microbiome, the bile
acid pool, and intestinal inflammation. For example, administra-
tion of saturated milk-derived fatty acids to mice specifically
increased taurocholate levels that provided a selective advan-
tage in growth of Bilophilia wadsworthia, a sulphite-reducing
pathobiont (Devkota et al., 2012). Consistent with this proposal,660 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.oral administration of taurocholate, but not glycocholate, in-
creased the growth of B wadsworthia and increased inflamma-
tion and colitis in genetically susceptible mice (Devkota et al.,
2012). Additional studies will be required to determine whether
these latter findings in rodents are applicable to humans.
Farnesoid X Receptor, the First Bile Acid-Responsive
Receptor
The identification of the nuclear receptor farnesoid X receptor
(FXRa, NR1H4, hereafter called FXR) (Forman et al., 1995; Seol
et al., 1995) and the subsequent demonstration that bile acids
were the endogenous ligands for FXR (Makishima et al., 1999;
Parks et al., 1999; Wang et al., 1999) were critical to our
understanding of the molecular mechanisms that control bile
acid metabolism. The rank order of potency of bile acids as
FXR agonists is shown in Table 1. However, the synthesis of
numerous FXR-specific agonists, including GW4064, 6a-ethyl-
chenodeoxycholic acid (6-ECDCA; INT-747; obeticholic acid),
fexaramine, andGSK2324 (Porez et al., 2012), has proven partic-
ularly important in overcoming the broader effects of bile acids
on metabolism.
FXR is one of 48 members of the human nuclear receptor
superfamily of transcription factors. Rodents express one addi-
tional member, FXRb (NR1H5), which is activated by lanosterol
but insensitive to bile acids (Sonoda et al., 2008). In contrast,
human FXRb is a pseudogene. FXR, like many of the nuclear
receptors, contains a DNA binding domain (DBD), a ligand bind-
ing domain (LBD), and additional activation domains (Calkin and
Tontonoz, 2012; Sonoda et al., 2008). There are four human and
mouse FXR isoforms that result from alternative promoter usage
and alternative RNA splicing (Zhang and Edwards, 2008). The
relative expression of these isoforms differs in FXR-rich tis-
sues/cells that are limited to hepatocytes, enterocytes in the
ileum, and renal tubules, all of which are known to be involved
in bile acid metabolism (Forman et al., 1995). In contrast,
although FXR is highly expressed in the adrenal gland, this organ
has no known role in bile acid metabolism. It also remains to be
established whether the very low levels of FXR reported to be
present in peripheral tissues such as adipose tissue, heart,
pancreatic b cells, and the artery wall are sufficient to directly
affect gene expression and metabolism in vivo. Generation of
mice with specific deletion of FXR in these latter tissues might
help determine the importance of this nuclear receptor in these
tissues.
FXR binds to specific DNA response elements (FXREs) as
an obligate heterodimer with RXR (Kalaany and Mangelsdorf,
2006). Genome-wide analysis of FXR binding sites revealed
that only 10% of FXREs are present in proximal promoters of
target genes, while most FXREs (90%) were in introns or inter-
genic regions (Chong et al., 2010; Thomas et al., 2010). Further
analysis indicates that FXR regulates genes involved in many
metabolic pathways, in addition to the well-established role of
FXR in regulating bile acid homeostasis (Figure 2).
The Role of FXR in Regulating the Enterohepatic
Circulation
The first description of the bile acid-dependent negative feed-
back loop was provided in the 1960s, when oral administration
of bile acids to rodents was shown to repress bile acid synthesis
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understanding of the many genes involved in the enterohepatic
circulation, we now have a detailed but incomplete understand-
ing of the molecular mechanisms involved in this intricate and
elegant negative feedback loop.
Repression of Cyp7a1 mRNA levels by bile acids was largely
attenuated in Fxr–/– mice, demonstrating a critical role of FXR in
bile acid synthesis (Sinal et al., 2000). This feedback mechanism
leading to repression of both Cyp7a1 and Cyp8b1 involves at
least two distinct mechanisms. The first involves bile acid
activation of hepatic FXR, leading to increased expression of
small heterodimer partner (SHP, NR0B2), an unusual member
of the nuclear hormone receptor family that lacks a DBD and
functions as a transcriptional repressor (Zhang et al., 2011a).
In the liver, SHP antagonizes the effects of liver receptor homo-
log 1 (LRH-1) and hepatocyte nuclear factor 4 alpha (HNF4a)
that positively regulate the expression of Cyp7a1 and Cyp8b1,
the rate-limiting enzymes in the synthesis of CDCA and CA
(Figure 2A) (Chiang, 2009). Unexpectedly, treatment of Shp–/–
mice with bile acids resulted in partial repression of Cyp7a1
and Cyp8b1 mRNA levels, suggesting the presence of an addi-
tional, SHP-independent mechanism(s) of repression (Kerr et al.,
2002; Wang et al., 2002).
A second mechanism for the feedback inhibition of bile acid
synthesis involves fibroblast growth factor 15 (FGF15 in mouse)
or the human homolog FGF19 (Inagaki et al., 2005). FGF15 and
FGF19 are unusual members of the FGF family, since they are
secreted into the blood and require a membrane-bound core-
ceptor protein (b-Klotho) in order to activate the FGF receptor
FGFR4 (Figures 2A and 2B) (Angelin et al., 2012; Jones, 2012;
Potthoff et al., 2012).
Initial studies revealed that treatment of human hepatocytes
with an FXR agonist led to a robust induction and secretion of
FGF19 (Holt et al., 2003; Jones, 2012). However, subsequent
studies indicated that levels of FGF19 mRNA in normal human
or mouse livers were low/undetectable (Schaap et al., 2009).
Nonetheless, the finding that FGF19mRNA levels were detected
in the livers of patients with extrahepatic cholestasis caused by a
pancreatic tumor suggests a possible autocrine role for the
hepatic FGF19, at least under these conditions (Schaap et al.,
2009).
In contrast, the expression of FGF15/19 is high in enterocytes
lining the distal ileum (Figure 2B) (Inagaki et al., 2005; Jones,
2012). Numerous experimental approaches indicate that activa-
tion of intestinal FXR by reabsorbed bile salts induces the
expression and subsequent secretion of FGF15/19 into the cir-
culation. FGF15/19 then binds to the FGFR4/b-Klotho complex
on the hepatocyte plasma membrane to initiate an intracellular
signaling cascade involving JNK that represses Cyp7a1 mRNA
and bile acid synthesis (Figures 2A and 2B) (Inagaki et al.,
2005; Jones, 2012; Kong et al., 2012). Support for this model
comes from genetic studies showing that Fgfr4–/– or bKlotho–/–
mice have elevated Cyp7a1 and Cyp8b1 mRNA levels and
increased, unregulated bile acid synthesis (Ito et al., 2005; Yu
et al., 2000), and from the observation that treatment of intesti-
nal Fxr–/– mice with specific FXR agonists fails to fully repress
Cyp7a1 and Cyp8b1 expression (Kong et al., 2012). Further
support for the model comes from studies showing that treat-
ment of Cynomolgus monkeys with an FGF19 antibody leadsto increased bile acid synthesis and excretion (Pai et al.,
2012). Furthermore, in humans, plasma FGF19 levels exhibit a
circadian rhythm that modulates hepatic bile acid synthesis
(Ga¨lman et al., 2011; Lunda˚sen et al., 2006). Thus, extensive
data support the hypothesis that intestinally derived FGF15/19
controls hepatic bile acid synthesis in rodents and primates.
Nonetheless, quantification of plasma levels of FGF15 protein
in mice under various conditions would provide a missing piece
of the puzzle, supporting the role of FGF15 in bile acid meta-
bolism, gall bladder filling, and glucose metabolism (Angelin
et al., 2012). Although both SHP and FGF15/19 clearly play
important roles in the repression of bile acid synthesis, the rela-
tive physiological importance of these two pathways in humans
remains to be determined.
An additional role for FGF15, and by extension, bile acids, was
identified when it was shown that gall bladders of Fgf15–/–,
Fgfr4–/–, and b-Klotho–/– mice are smaller than those of wild-
type mice (Choi et al., 2006; Kong et al., 2012; Potthoff et al.,
2012). These observations suggest that FGF15 protein, secreted
from intestinal enterocytes following activation of FXR, binds to
FGFR4/b-Klotho on the smooth muscle cells of the gall bladder
to promote increased intracellular signaling and relaxation,
thereby allowing the refilling of the gall bladder in a timely
manner.
Bile acid-dependent activation of FXR also regulates other as-
pects of the enterohepatic circulation. In the liver, activated FXR
induces the expression of the transporters BSEP/ABCB11,
MDR3/MDR2/ABCB4, and ABCG5/ABCG8 that function to
efflux bile salts, phospholipids, and cholesterol, respectively,
into the biliary canaliculi (Figure 2A). At the same time, the
expression of the bile acid importer NTCP is also repressed,
thus limiting the transport of bile salts from the blood into the
hepatocytes (Figure 2A). The mechanism for NTCP repression
appears to depend on expression of the transcriptional re-
pressor SHP (Denson et al., 2001). Thus, activation of hepatic
FXR promotes the increased efflux of bile salts, coupled with
decreased bile acid synthesis and decreased reuptake of bile
salts from the blood. Together, these changes maintain bile
acid levels in the biliary tree and intestine appropriate for lipid
absorption, while at the same time limiting the hepatic accumu-
lation of bile acids to toxic levels.
In the postprandial state, the bile salts in the lumen of the small
intestine are resorped via the transporter ASBT on the surface of
enterocytes in the distal ileum (Figure 2B). Within the nucleus of
the enterocytes, the bile salts activate FXR, leading to induction
of intestinal FXR target genes that include Ibabp, Osta, Ostb,
Shp, and Fgf15/19 (Figure 2B) (Matsubara et al., 2013). Repres-
sion of ASBT, likely via increased levels of SHP (Dawson et al.,
2003), limits excessive uptake of potentially toxic bile acids.
Studies with gene-targeted mice, or humans with inactivating
mutations in ASBT, indicate that both ASBT and the OSTa/
OSTb heterodimer are essential for transporting bile salts from
the intestinal lumen into the portal blood (Figure 2B) (Dawson
et al., 2003; Oelkers et al., 1997; Rao et al., 2008). In conclusion,
FXR present in hepatocytes and enterocytes functions to
monitor cellular bile acid/salt levels and to alter gene expression
in order to maintain the enterohepatic circulation of bile salts/
acids while at the same time preventing cellular accumulation
to toxic levels.Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 661
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Although not part of the enterohepatic circulation, the kidney
also plays a role in conserving bile acids (Dawson et al., 2010;
Wang et al., 2009b). Indeed, FXR is highly expressed in the
proximal and distal collecting tubules, where it is thought to
regulate genes involved in bile acid resorption, lipid metabolism,
and inflammation (Wang et al., 2009b). Cells of the proximal col-
lecting tubules also express ASBT on their apical surface that
likely functions to resorb and thus conserve bile acids under
normal conditions (Zollner and Trauner, 2006). Presumably,
the transmembrane heterodimer OSTa/OSTb that is induced
following activation of renal FXR (Higashiyama et al., 2008; Lee
et al., 2006; Zollner and Trauner, 2006) transports these bile
acids back into the blood (Boyer et al., 2004; Dawson et al.,
2010). Under certain conditions, the capacity for renal reabsorp-
tion of bile acids may be limiting, as patients with cholestasis
have elevated levels of bile acids both in the urine and peripheral
blood (Trottier et al., 2011). It is not knownwhether bile acids play
a more specific role in the kidney.
FXR Activation Modulates Several Distinct Metabolic
Pathways
Studies in which humans were administered bile acids and/or
wild-type or Fxr–/– mice were treated with FXR-specific agonists
indicate that FXR regulates the metabolism of plasma lipopro-
teins, glucose, steatosis, inflammation, bacterial growth, and
liver regeneration, in addition to the regulation of bile acid
homeostasis. Evidence from limited clinical trials suggests that
FXR agonists may have beneficial effects in humans.
(1) Lipoprotein Metabolism
The original characterization of Fxr–/– mice suggested that FXR
also controls lipid metabolism, as these mice had elevated
hepatic lipids as well as increased plasma triglycerides, choles-
terol, free fatty acids, and lipoproteins (VLDL and LDL) (Sinal
et al., 2000). Conversely, treatment of diabetic (db/db), obese
(ob/ob), or wild-type mice, but not Fxr–/– mice, with bile acids
or specific FXR agonists lowered plasma triglyceride, fatty acids,
and cholesterol and decreased hepatic lipid levels/steatosis
(Watanabe et al., 2004; Zhang et al., 2006). The decrease in
plasma lipoprotein levels appears to be due in part to FXR-
dependent induction of hepatic genes involved in lipoprotein
clearance from the plasma. These include SR-B1 (Scarb1; the
HDL receptor), the VLDL receptor, syndecan-1, and apoC-II, a
cofactor for lipoprotein lipase that hydrolyses plasma triglycer-
ides (Calkin and Tontonoz, 2012; Zhang and Edwards, 2008).
Activated FXR also leads to repression of hepatic SREBP-1c, a
critical transcription factor necessary for the synthesis of fatty
acids and triglycerides, thus decreasing synthesis of these lipids
(Watanabe et al., 2004; Zhang and Edwards, 2008). Interestingly,
decades before the identification of the FXR pathway, patients
who were given oral doses of CDCA over many months to
gradually dissolve cholesterol gallstones exhibited reduced
levels of plasma triglyceride (Iser and Sali, 1981). In retrospect,
it seems likely that the reduction in plasma triglycerides was a
result of activation of hepatic FXR by the CDCA.
(2) Glucose Metabolism
Bile acid activation of FXR regulates glucose metabolism by
improving insulin sensitivity and repressing hepatic gluconeo-
genesis. The earlier finding that Fxr–/– mice are insulin resistant662 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.suggested a role for FXR in glucose metabolism (Cariou et al.,
2006; Ma et al., 2006; Zhang et al., 2006). Consistent with this
observation, treatment of wild-type or diabetic db/db or insu-
lin-resistant ob/obmice, but not Fxr–/–mice, with CA or FXR-spe-
cific agonists improved insulin sensitivity and reduced plasma
glucose levels (Cariou et al., 2006; Ma et al., 2006; Zhang
et al., 2006). These changes appear to result partly from the
FXR-dependent repression of hepatic Pepck and G6Pase
expression and gluconeogenesis, as well as an FXR-dependent
increase in glycogen synthesis (reviewed in Calkin and Tontonoz,
2012). More recent studies indicate that FGF15, secreted from
the ileum following activation of FXR, has insulin-like actions
including inhibition of hepatic gluconeogenesis (Kir et al., 2011;
Potthoff et al., 2011; Potthoff et al., 2012; Schaap, 2012). As dis-
cussed below, bile acids also reduce plasma glucose levels and
increase insulin sensitivity following activation of the G protein-
coupled receptor TGR5 (Choi et al., 2006; Potthoff et al., 2012).
(3) Cholestasis, Inflammation, and Hepatoprotection
Cholestasis results in the intrahepatic accumulation of cytotoxic
bile acids leading to increased inflammatory cytokines and liver
injury (Zhang et al., 2012). The elevated levels of intracellular bile
acids are expected to activate both FXR and PXR (see below).
Activation of FXR was shown to provide hepatoprotection from
bile duct ligation or a-naphthylisothiocyanate, both of which
have been used as models of cholestasis (Liu et al., 2003),
or from a challenge with high levels of acetaminophen (Lee
et al., 2010). Such protection likely results from FXR-dependent
induction of several phase I–III genes involved in xenobiotic
metabolism (Lee et al., 2010; Matsubara et al., 2013). Very
recently, Bennett and colleagues showed that bile acids induce
the expression of flavin-monooxygenase 3 (Fmo3) in a mecha-
nism that requires FXR. FMO3 is an enzyme previously thought
to be part of the detoxification pathway but was shown to be
required for the synthesis of trimethylamine-N-oxide (TMAO), a
metabolite that is strongly associated with atherosclerosis in
mice and humans (Bennett et al., 2013).
Bile Acids Activate the Pregnane X Receptor (PXR)
and the Vitamin D Receptor (VDR)
In addition to FXR, two other nuclear receptors, PXR (NR1I2) and
VDR (NR1I1), are activated by specific bile acids.
(1) PXR
PXR is highly expressed in the liver and intestine, with lower
levels in many other tissues. The functional PXR/RXR hetero-
dimer is promiscuous, as it is activated by numerous xenobi-
otics, pharmaceutical drugs, and specific bile acids. In contrast
to FXR, which is activated by a number of bile acids (CDCA >
DCA > LCA [ CA; unresponsive to LCA) (Makishima et al.,
1999; Parks et al., 1999), PXR is activated by the hepatotoxic
bile acid LCA and 3-keto-LCA (EC50 10 mM) (Table 1) and is
unresponsive to CDCA, DCA, or CA (Staudinger et al., 2001).
Activation of PXR induces phase I–III genes involved in meta-
bolism, transport, and excretion of many compounds including
xenobiotics and toxic bile acids such as LCA. However, the rela-
tive importance of hepatic and intestinal PXR activation in
response to either LCA or 3-keto-LCA in vivo remains to be
determined. A recent report demonstrated that intestinal PXR
provided protection against inflammatory bowel disease as a
result of attenuated expression of NFkB and reduced expression
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acids provide a similar PXR-dependent protective effect against
inflammatory bowel disease will require additional investiga-
tions.
(2) VDR
VDR is expressed in multiple tissues including the kidney,
intestine, and macrophages, where it controls numerous physi-
ological and pharmacological processes, which include not
only bone and calcium metabolism but also immunity, cellular
growth, and differentiation. The most potent endogenous
agonist of VDR is 1,25-dihydroxyvitamin D3 (1,25 diOHD3).
Unexpectedly, the toxic bile acid LCA, as well as 3-keto LCA,
was shown to activate VDR target genes, includingCYP3A family
members, which are involved in themetabolism of LCA and other
toxins to less toxic and biologically inactive products (Makishima
et al., 2002) (Table 1).
Vitamins A and D are both lipid-soluble vitamins that depend
on bile salts for normal absorption. Unexpectedly, these two
vitamins were shown to be part of different feedback mecha-
nisms that repress bile acid synthesis. Schmidt et al. reported
that activation of VDR in enterocytes resulted in increased secre-
tion of FGF15 and subsequent repression of hepaticCyp7a1 by a
process that required an intact FXR pathway (Schmidt et al.,
2010). Consistent with these results, these authors reported
that Vdr–/– mice have increased levels of hepatic Cyp7a1 and
Cyp8b1, an increased bile acid pool size, and decreased Fgf15
expression in enterocytes. At the present time it is not known
whether the decrease in Fgf15 noted in Vdr–/– mice is sufficient
to impair the FGF15-dependent filling of the gallbladder. How-
ever, these results indicate that VDR in the intestine can modu-
late hepatic bile acid synthesis.
Bile Acid-Responsive G Protein-Coupled Receptor,
TGR5
Interest in bile acids as hormones was further stimulated a
decade ago when two groups independently identified a plasma
membrane-bound G protein-coupled receptor that was acti-
vated by low levels (1–10 mM) of bile acids (Kawamata et al.,
2003; Maruyama et al., 2002). This bile acid-responsive receptor
has been referred to as membrane-type bile acid receptor
(M-BAR), G protein-coupled bile acid receptor 1 (GPBAR1),
GPR131, and the most commonly used name, TGR5. In contrast
to FXR, hydrophobic bile acids are the most potent activators of
TGR5, with taurine conjugation further increasing their potency
(EC50 of 0.29–10 mM) (Table 1) (Keitel and Ha¨ussinger, 2012;
Maruyama et al., 2002; Pols et al., 2011b; Sato et al., 2008).
Identification and characterization of the specific roles of TGR5
in vivo have been greatly aided by the synthesis of specific
TGR5 agonists, such as INT-777 (6-methyl-23-methyl-CDCA ;
EC50 = 0.58 mM) (Sato et al., 2008), the discovery that oleanolic
acid isolated from olive leaves is a natural agonist, and the
generation of Tgr5–/– mice (Keitel and Ha¨ussinger, 2012; Porez
et al., 2012; Thomas et al., 2009).
TGR5 is highly expressed in nonparenchymal cells of the liver,
which include the gallbladder epithelial cells, cholangiocytes
(epithelial cells of the bile duct), sinusoidal epithelium, and
Ku¨pffer cells, as well as immune cells (Keitel and Ha¨ussinger,
2011). However, TGR5 is also expressed in many other tissues,
including brown adipose tissue, intestinal enteroendocrine cellsthat secrete the incretin hormone glucagon-like peptide-1
(GLP-1), enteric neurons, and the brain (Keitel et al., 2010; Keitel
and Ha¨ussinger, 2012; Vassileva et al., 2006). Activation of TGR5
results in receptor internalization, increased cAMP levels, and
activation of protein kinase A, leading to increased phosphoryla-
tion of target proteins, including the cAMP response element
binding protein (CREBP) transcription factor (Nguyen and Bous-
carel, 2008; Pols et al., 2011b; Porez et al., 2012). The results of
such activation are broad and cell specific and include anti-
inflammatory effects in macrophages, increased energy expen-
diture in brown adipose tissue, improved glucose metabolism
and insulin sensitivity, gall bladder relaxation, and increased
intestinal motility. The role of TGR5 in the brain is likely indepen-
dent of bile acids. The finding that TGR5 also responds to
nanomolar concentrations of the neurosteroid 5b-pregnane-
3a-ol-20-one (Keitel et al., 2010) raises the possibility that addi-
tional endogenous agonists may coexist in the circulation.
(1) TGR5 and the Immune System
A role for TGR5 in the immune system was discovered when it
was shown that activation of TGR5 on isolated macrophages or
in mice suppressed the release of proinflammatory cytokines,
such as interleukin-1a and interleukin-6, in response to LPS (Ka-
wamata et al., 2003; Keitel et al., 2008; Wang et al., 2011). The
mechanism involves a TGR5-dependent decrease in the phos-
phorylation of an inhibitor of nuclear factor kB (NFkB), thus pre-
venting the nuclear translocation NFkB-p65 and reducing the
transcription of proinflammatory cytokines by NFkB (Pols et al.,
2011a; Wang et al., 2011). The physiological importance of
the anti-inflammatory effects of macrophage TGR5 was further
elucidated following transplantation of bone marrow from wild-
type or Tgr5–/– mice into recipient Ldlr–/– and Ldlr–/–Tgr5–/– mice
(Pols et al., 2011a). Treatment of the transplanted mice with a
TGR5 agonist attenuated both the levels of proinflammatory
cytokines and atherosclerosis in Ldlr–/–, but not in Ldlr–/–
Tgr5–/–mice. These studies identify an important physiological
role for macrophage TGR5 in suppressing cytokine expression
and reducing disease in mice (Pols et al., 2011a). Whether this
finding can be exploited in humans remains unknown, as clinical
trials with TGR5 agonists have yet to be reported.
(2) TGR5 and Energy Metabolism
Early evidence that TGR5 influences energy metabolism came
from feeding rodents a high-fat diet supplemented with CA.
The supraphysiological bile acid levels achieved in blood re-
sulted in decreased obesity and insulin resistance (Watanabe
et al., 2006). A mechanism for the decreased obesity was postu-
lated to involve bile acid-dependent activation of TGR5 in brown
adipose tissue leading to an increase in energy expenditure.
TGR5, via increased cAMP, activated type 2 iodothyronine deio-
dinase (DIO2), leading to increased levels of active thyroid hor-
mone (Watanabe et al., 2006). These effects could be mimicked
by treatment of mice with INT-777, a TGR5-specific agonist, but
not with the FXR agonist GW4064 (Thomas et al., 2009), thus
identifying TGR5 as the essential receptor. The significance of
TGR5 as an important regulator of energy expenditure is sup-
ported by the findings that female Tgr5–/– mice fed a high-fat
diet are more obese than controls (Maruyama et al., 2006) and
that administration of a TGR5 agonist to wild-type mice reduced
obesity and glucose levels in response to a high-fat diet (Sato
et al., 2007).Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc. 663
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Numerous studies have shown that activation of TGR5 in high-
fat-fed wild-type or TGR5-transgenic mice lowers plasma
glucose, enhances glucose tolerance, and increases insulin
sensitivity. Despite the finding that basal plasma glucose levels
are normal in chow-fed Tgr5–/– mice, these data identify a role
for TGR5 in regulating carbohydrate metabolism (Sato et al.,
2007; Thomas et al., 2009). Current evidence indicates that
the mechanism involved in the control of glucose homeostasis
is indirect and requires activation of TGR5 on intestinal enter-
oendocrine L cells, leading to secretion of GLP-1 into the circu-
lation. It is hypothesized that GLP-1 then binds to the GLP-1
receptor in the liver, leading to the improved insulin sensitivity
(Katsuma et al., 2005; Keitel and Ha¨ussinger, 2012; Thomas
et al., 2009). Important confirmation of this pathway would be
gained from studies utilizing mice that lack TGR5 in enteroendo-
crine L cells. At the current time, it is unclear whether TGR5
agonists might provide an alternative treatment for type 2
diabetes.
(4) Bile Acid Sequestrants, TGR5, and Glycemic Control
Bile acid sequestrants are approved for treatment of patients
with hypercholesterolemia. These resins bind bile acids in the
intestinal lumen and consequently impair bile acid resorption,
thus interrupting the enterohepatic circulation of bile acids. The
result is increased bile acid excretion, reduced plasma LDL
levels, and, in type 2 diabetic patients, decreased plasma
glucose and increased insulin sensitivity (Staels et al., 2010). A
mechanism to explain the improved control of plasma glucose
levels was recently identified when it was shown that treatment
of mice with a bile acid sequestrant led to increased secretion
of preproglucagon, the precursor of GLP-1, from the colon of
wild-type but not Tgr5–/– mice (Harach et al., 2012). It was pro-
posed that the increased levels of bile acids in the colon after
bile acid sequestrant treatment were sufficient to activate
colonic TGR5 and enhance plasma GLP-1 levels (Harach et al.,
2012). If a similar mechanism exists in humans, it may explain
at least in part, the hypoglycemic effects observed when type
2 diabetics are treated with bile acid sequestrants.
(5) TGR5, Gall Bladder Filling, and Fluid Secretion
TGR5 protein is present on the surface of cholangiocytes, on the
epithelial cells lining the gall bladder, on smooth muscle cells,
and on intracellular recycling endosomes (Keitel et al., 2009; Kei-
tel and Ha¨ussinger, 2012). TGR5 expressed on these cells in the
biliary tree controls fluid and chloride secretion by the epithelial
cells, as well as postprandial relaxation of the gallbladder prior
to refilling with bile.
One mechanism was revealed when treatment of human
gallbladder tissue or murine gallbladder epithelial cells with
TGR5 agonists was shown to activate the cystic fibrosis trans-
membrane conductance regulator (CFTR) and increase chloride
secretion (Keitel et al., 2009). Based on these and a number of
other studies, Keitel and Haussinger recently proposed that
TGR5 may function as a bile acid sensor that links bile acid con-
centration in the biliary tree to bile acid absorption and fluid
secretion (Keitel and Ha¨ussinger, 2012).
The finding that Tgr5–/– mice have smaller gallbladders than
wild-type mice, especially after feeding a CA-enriched diet, sug-
gested a role for this G protein-coupled receptor in gall bladder
filling (Li et al., 2011). Consistent with this model, treatment of664 Cell Metabolism 17, May 7, 2013 ª2013 Elsevier Inc.wild-type but not Tgr5–/–mice with a TGR5 agonist caused relax-
ation of biliary smooth muscles and gallbladder filling (Lavoie
et al., 2010; Li et al., 2011). Thus, there are two bile acid-depen-
dent pathways that promote gallbladder relaxation following
contraction and release of bile into the duodenum in response
to CCK. One pathway involves bile acid activation of TGR5
expressed on the surface of smooth muscle cells of the gall
bladder, and the second involves FGF15/19-dependent activa-
tion of FGFR4/b-Klotho on the gall bladder following release of
the hormone from enterocytes.
A broader role for TGR5 in bile acid metabolism is suggested
by the finding that Tgr5–/– mice have a reduced bile acid pool
size, despite normal bile acid synthesis. These mice are also
resistant to gallstone formation following administration of a
lithogenic diet (Vassileva et al., 2006). However, themechanisms
leading to these changes have yet to be identified.
(6) TGR5 and Intestinal Motility
Luminal concentrations of bile salts are known to affect intesti-
nal motility (Hofmann, 2010). Based on recent studies with
Tgr5–/– mice, TGR5 transgenic mice, and TGR5 agonists, it
appears that normal peristalsis and transit time in the colon
are dependent upon activation of TGR5 on enterochromaffin
cells and inhibitory colonic neurons. Thus, transit time is
decreased and constipation increased in Tgr5–/– mice (Alemi
et al., 2013). The generation of tissue-specific TGR5 knockout
mice that lack TGR5 in enterochromaffin cells and inhibitory
neurons would provide a powerful model to further substantiate
this hypothesis.
Clinical Applications: Alteration of Bile Acid
Homeostasis and FXR- or TGR5-Specific Agonists
For more than 3,000 years, bear bile has been used in traditional
Chinese medicine to treat various ailments. Unfortunately, in
most cases the bile is obtained from live bears housed under
appalling conditions. Sadly, bear farming and distribution of their
bile continues, despite being illegal in many countries, including
the USA.
In Western medicine, oral administration of pure, chemically
synthesized CDCA or UDCA has been used for only four
decades. One of the earliest uses in modern clinical medicine
involved chronic oral administration of bile acids (originally
CDCA but subsequently UDCA) over months or years to patients
with cholesterol gallstones (Table 2) (Iser and Sali, 1981). The
change in the bile acid pool slowly solubilized the cholesterol
gallstones in the gall bladder or ducts. However, the efficacy of
UDCA is limited, and this approach has been largely replaced
by surgery. Oral administration of UDCA or nor-UDCA are also
approved treatments to improve liver function in patients with
primary biliary cirrhosis or sclerosing cholangitis, respectively
(Table 2). UDCA has also been successfully used to prevent
the occurrence of fatal veno-occlusive disease (VOD), a type of
graft versus host reaction, in recipients of bone marrow trans-
plants (Ruutu et al., 2002).
Inborn errors of nine of the bile acid synthetic genes have
been identified, resulting in impaired bile acid synthesis and
accumulation of intermediates (Heubi et al., 2007). The clinical
symptoms of such inborn errors are heterogeneous. Patients
may present with cholestasis, malabsorption of lipids and vita-
mins, fibrosis, neurological disease, or hypercholesterolemia,
Table 2. Bile Acids and FXR Agonists: Current Clinical Status
Compound Clinical Status Target Target Disease Effect
Bile acid (BA) sequestrant Approved Increased BA excretion Hyperlipidemia Increased hepatic LDLR
Type 2 diabetes Decreased plasma LDL
Increased insulin sensitivity
Cholic acid Approved Provide bile acids (BAs) for
lipid absorption
Inborn errors of BA metabolism
that inhibit BA synthesis
Increased lipid absorption
CDCA Approved Replacement BA Cerebrotendinous xanthomatosis Improved liver function
Reduce endogenous BA synthesis
UDCA Approved Gallstone dissolution Gallstones Solubilize cholesterol gallstones
UDCA Approved Liver Primary biliary cirrhosis (PBC) Improved liver function
INT-747 (6-ECDCA;
obeticholic acid/OCA)
Phase III (2011) FXR Type 2 diabetes Improved insulin sensitivity
OCA Phase I (2011) FXR Nonalcoholic steatohepatitis
(NAFLD)
Improved insulin sensitivity
Improved liver function
OCA Phase III (2011) FXR PBC Improved liver function
PX-102 Phase I (2011) FXR Metabolic syndrome Improved insulin sensitivity
NAFLD Improved liver function
nor-UDCA Phase I (2011) Liver Sclerosing cholangitis Improved liver function
Clinically approved treatments that involve bile acid sequestrants, bile acids, or specific FXR agonists are listed, together with their target disease and
real or potential beneficial effect. Where noted, FXR agonists are in phase I–III clinical trials. LDL, low-density lipoprotein; LDLR, LDL receptor.
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morbidity rates (Heubi et al., 2007). Treatment of some disorders
by oral administration of CA or CDCA improves lipid adsorption,
prevents liver injury, and inhibits the synthesis of toxic bile acid
intermediates, thus providing an alternative to liver transplanta-
tion (Table 2) (Heubi et al., 2007).
A number of clinical trials (phases I–III) have been undertaken
using the synthetic FXR agonists INT-747 (6-ECDCA; obeticholic
acid), FXR-450, or PX-102 (Table 2) (Porez et al., 2012). Although
no detrimental effects were reported, larger-scale clinical trials
will be necessary to assess whether FXR-specific agonists will
prove useful in the treatment of type 2 diabetes, metabolic syn-
drome, nonalcoholic steatohepatitis, or primary biliary cirrhosis.
To our knowledge, no clinical trials have been completed with
synthetic agonists for TGR5.
Summary and Future Perspectives
The proposal that bile acids might activate three nuclear recep-
tors and a G protein-coupled receptor and bring about broad
changes in metabolism would have met with considerable skep-
ticism before 1999. However, a recent study in which treatment
of primary rodent hepatocytes with bile salts led to activation of
ERK1/2, in a sphingosine-1-phosphate receptor-dependent
pathway (Studer et al., 2012), suggests that other bile acid re-
ceptors remain to be identified. In this latter case, the generation
and analysis of mice that lack this, or other potential bile acid
receptors, will be particularly important.
The understanding of the role bile acids play in human health
and disease will likely benefit from recent advances in tech-
nology that have enabled genome-wide association studies
(GWAS) of disorders of bile acid metabolism. Numerous
GWAS have been carried out for bile acid disorders, including
biliary artesia (Garcia-Barcelo´ et al., 2010), gallstones (Buch
et al., 2007), gall bladder cancer (Cha et al., 2012), and primarybiliary cirrhosis (Liu et al., 2010; Mells et al., 2011; Nakamura
et al., 2012). Some associations have identified genes known
to affect the disease; for example, gallstones were associated
with variations at the ABCG5/G8 locus, the transporter involved
in biliary cholesterol efflux (Buch et al., 2007). However, many
loci contain genes not known to be associated with bile acid
metabolism. For example, inflammatory genes were identified
in the GWAS for primary biliary cirrhosis (Liu et al., 2010; Mells
et al., 2011). Genes involved in bile acid metabolism have also
been associated with other traits such as the association of
CYP7A1 with total and LDL cholesterol (Teslovich et al., 2010).
The expansion of these studies will likely open up many new
avenues for discovery of novel genes involved in bile acid
metabolism.
The finding that initial phase I–III clinical trials to test the effi-
cacy of FXR agonists have been successful is reason for opti-
mism. However, the development of clinically useful agonists
for FXR and TGR5 appears to be particularly challenging given
that these bile acid receptors are present in many tissues where
they affect numerous genes and distinct metabolic pathways. In
this regard, the development of tissue-selective agonists for FXR
or TGR5 may prove to be important, as their use may limit un-
wanted side effects. Finally, when we consider the numerous
novel physiological functions of bile acids that have been identi-
fied in the last 13 years, it seems highly likely that many more
remain to be discovered.ACKNOWLEDGMENTS
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